SCHEMBL3404948

SCHEMBL3404948

CCN(C)CCN(CC)C(=O)c1sc(-c2ccc(Cl)cc2)nc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
RAB9A P51151 7/20 0.56
NPC1 O15118 5/20 0.56
KDM4E B2RXH2 2/20 0.56
POLB P06746 1/20 0.56
MAPT P10636 9/20 0.55
ALDH1A1 P00352 6/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
GAA P10253 2/20 0.55
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.47
LMNA P02545 1/20 0.47
XDH P47989 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401729 0.91 RAB9A (0.54) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3402280 0.90 CDC7 (0.44) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3403051 0.89 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL13071478 0.89 CDC7 (0.44) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3398655 0.89 TRPM8 (0.47) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3400511 0.88 NPC1 (0.43) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3404718 0.87 KMT2A (0.60) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3404918 0.87 MAPT (0.50) SMN1; SMN2RAB9ANPC1KDM4EMAPT
SCHEMBL3405629 0.87 CRHR1 (0.43) SMN1; SMN2RAB9ANPC1KDM4EPOLB
SCHEMBL3405333 0.85 RAB9A (0.40) SMN1; SMN2RAB9ANPC1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 SMN1; SMN2 1605/4885RAB9A 2102/4885NPC1 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.